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The highly conserved ubiquitin–proteasome system is the principal machinery for extralysosomal protein degradation in eukaryotic cells. The
26S proteasome, a large multicatalytic multisubunit protease that processes cell proteins by limited and controlled proteolysis, constitutes the
central proteolytic component of the ubiquitin–proteasome system. By processing cell proteins essential for development, differentiation,
proliferation, cell cycling, apoptosis, gene transcription, signal transduction, senescence, and inflammatory and stress response, the 26S
proteasome plays a key role in the regulation and maintenance of basic cellular processes. Various synthetic and biologic inhibitors with different
inhibitory profiles towards the proteolytic activities of the 26S proteasome have been identified recently. Such proteasome inhibitors induce
apoptosis and cell cycle arrest preferentially in neoplastic cells. Based on these findings proteasome inhibitors became useful in cancer therapy.
However, under the pressure of continuous proteasome inhibition, eukaryotic cells can develop complex adaptive mechanisms to subvert the lethal
attack of proteasome inhibitors. Such mechanisms include the adaptive modification of the proteasome system with increased expression,
enhanced proteolytic activity and altered subcomplex assembly and subunit composition of proteasomes as well as the expression of a giant
oligomeric protease complex, tripeptidyl peptidase II, which partially compensates for impaired proteasome function. Here we review the adaptive
mechanisms developed by eukaryotic cells in response to proteasome inhibition. These mechanisms reveal enormous flexibility of the proteasome
system and may have implications in cancer biology and therapy.
© 2007 Elsevier B.V. All rights reserved.Keywords: Proteasome; Proteasome inhibition; Proteasome inhibitor; Tripeptidyl peptidase II; Adaptive modification; Apoptosis resistance1. Introduction
The ubiquitin–proteasome system has been identified as the
cell's major tool for extralysosomal cytosolic and nuclear
protein degradation, and the subtle characterization of its
multiple biological functions has pointed out a new concep-
tional framework for understanding the regulation of basic
cellular processes by controlled and limited proteolysis of cell
proteins [1–6]. The 26S proteasome, a large multicatalytic
multisubunit protease complex, constitutes the central proteo-
lytic machinery of the ubiquitin–proteasome system and is
responsible for the degradation and proteolytic processing of
cell proteins essential for the regulation of development,⁎ Corresponding author. Tel.: +49 6221 564017; fax: +49 6221 564200.
E-mail address: cord.naujokat@med.uni-heidelberg.de (C. Naujokat).
0167-4889/$ - see front matter © 2007 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbamcr.2007.05.007differentiation, proliferation, cell cycling, apoptosis, gene
transcription, signal transduction, senescence, antigen presenta-
tion, immune activation, and inflammatory and stress response,
thereby governing basic cellular processes [[7,8,12,13]; Table 1].
Cell proteins destined to undergo processing by entering the
ubiquitin–proteasome pathway must be targeted for recognition
and subsequent degradation by the 26S proteasome by covalent
attachments of multiple monomers of the 76 amino acid
polypeptide ubiquitin. This process, called ubiquitination, takes
place in a multistep reaction and requires three classes of
enzymes (Fig. 1A): ubiquitin-activating enzymes (E1), ubiqui-
tin-conjugating enzymes (E2), and ubiquitin–protein ligases
(E3). E1 activate ubiquitin by forming a high-energy thiol ester
bond between an E1 active site-located cysteine residue and the
C-terminal glycine residue of ubiquitin in a reaction that
requires the hydrolysis of ATP. This activated ubiquitin moiety
is then transferred to E2 via the formation of an additional thiol
Table 1
Characteristics of the 26S proteasome and TPP II
26S Proteasome TPP II
Molecular mass ∼2000 kDa (20S proteasome: ∼700 kDa) N1000 kDa
Subunit composition 20S catalytic core complex capped at both ends
by 19S or 11S regulatory complexes
Oligomeric assembly
of identical 138 kDa subunits
Peptidase activities Main activities: trypsin-like, chymotrypsin-like, caspase-like; additional
activities: cleavage after branched chain amino acids, cleavage between
small neutral amino acids
Cleavage of tripeptides from the free
N-terminus of oligopeptides; preference for hydrophobic
amino acids in P1 position
Substrates Polyubiquitinated proteins;
Antigenic proteins (preferentially by immunoproteasomes)
Oligopeptides, antigenic peptides, cholecystokinin
Type of enzyme Threonine protease Serine peptidase of the subtilisin type
Subcellular localization Cytosol (extralysosomal), nucleus Cytosol (extralysosomal),
inner cytoplasmic membrane
Occurrence Eukaryotes; in bacteria and archaea: 20S proteasome;
homologues in bacteria and archaea: HsIV, ClpP, Lon
Eukaryotes; homologues in archaea: tricorn protease
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covalent attachment of ubiquitin to the target protein by the
formation of isopeptide bonds. Multiple cycles of ubiquitination
finally result in the synthesis and attachment of polyubiquitin
chains that serve as a recognition signal for the degradation of
the target protein by the 26S proteasome [1,3].
The proteolytic activities of the 26S proteasome occur in a
barrel-shaped 20S catalytic core complex composed of four
axially stacked rings (Fig. 1B). Each outer ring consists of
seven different non-proteolytic α subunits that allow con-
formational flexibility and substrate translocation into the
central cavity of the 20S complex; the two inner rings are
formed by seven different but related β subunits, giving the
complex the general stoichiometry of α1–7β1–7β1–7α1–7 [5, 6,
9]. Only β1, β2, and β5 subunits harbor proteolytic sites
formed by N-terminal threonine residues that face the central
cavity of the 20S complex [5,6]. Based on their specificity
toward oligopeptidyl substrates, β1, β2, and β5 subunits have
been defined to possess caspase-like, trypsin-like and
chymotrypsin-like peptidase activity, respectively [10,11].
During de novo biogenesis and assembly of the 20S complex,
the constitutively expressed β1, β2, and β5 subunits can be
replaced by IFN-γ-inducible homologous counterparts, the so-
called immunosubunits β1i (LMP2), β2i (MECL1), and β5i
(LMP7), leading to altered proteasomal cleavage site
preference and increased proteasomal production of antigenic
peptides for MHC class I presentation [12,13]. Both 20S
species, containing either the constitutive β1, β2, and β5
subunits or the IFN-γ-inducible β1i, β2i, and β5i immuno-
subunits, are incapable of degrading ubiquitin-conjugated and
folded substrate proteins [14]. However, they require for this
task 19S (PA700) or 11S (PA28) regulatory complexes bound
to the α rings and capping the 20S complex at both ends,
leading to the assembly of 19S–20S–19S (26S proteasome)
or 11S–20S–11S proteasome holoparticles [5,6]. The 19S
complex exhibits a sophisticated multisubunit assembly
consisting of six ATPase and at least eight non-ATPase
subunits, and is required for recognition, deubiquitination,
unfolding and translocation of substrate proteins before their
proteolytic degradation within the central cavity of the 20S
complex [15–18]. The 11S complex, also termed proteasomeactivator PA28, is an IFN-γ-inducible ring-shaped heptameric
assembly composed of three α and four β subunits [19–22].
IFN-γ-inducible PA28αβ attaches to the outer α rings of the
20S complex and largely enhances proteasomal production of
antigenic peptides for MHC class I presentation independently
of the presence of immunosubunits within the 20S complex.
Besides PA28αβ, a second kind of PA28, termed PA28γ,
exists. PA28γ is a heptameric assembly of γ subunits
structurally and functionally related to PA28αβ, but not
inducible by IFN-γ [12,13,23–25].
Mammalian cells usually harbor a heterogeneous popula-
tion of 20S complexes, which contain either the constitutive
proteolytic β1, β2, and β5 subunits or the IFN-γ-inducible
β1i, β2i, and β5i immunosubunits or a subunit composition
intermediate between constitutive and immuno 20S com-
plexes. Such 20S complexes can be further divided into
subtypes that differ with regard to their enzymatic properties,
subcellular localization and tissue distribution [26,27]. Similar
to the diversity of 20S complexes, proteasome holoparticles
exhibit three major species with different regulatory complex
assemblies and enzymatic characteristics: 19S–20S–19S,
PA28–20S-PA28, and 19S–20S–PA28, the latter referred to
as hybrid proteasomes [28,29]. Except for the IFN-γ-induced
expression of β1i, β2i, and β5i immunosubunits and PA28
that results in abundant biogenesis of immunoproteasomes,
mechanisms that regulate subunit composition, proteolytic
activity and the cellular repertoire and amount of proteasome
species under steady-state or stress conditions are still rather
unclear.
The identification and use of selective synthetic and
biologic inhibitors of proteasomal proteolytic activities [30–
32] (Table 2) have principally contributed to the identification
of essential functions of the 26S proteasome in various
processes and pathways of eukaryotic cells [7,33]. In
particular, inhibition of proteasomal activities by proteasome
inhibitors induces apoptosis preferentially in rapidly prolifer-
ating and neoplastic cells [7,34–36]. These findings have
recently paved the way for the use of proteasome inhibitors in
cancer therapy [37–39]. Moreover, proteasome inhibitors have
been shown to suppress survival, activation, proliferation and
cytokine synthesis of mouse and human T cells [30–44] and
Fig. 1. The ubiquitin–proteasome pathway (schematic). (A) Attachment of ubiquitin (Ub) to the target protein requires three major enzymatic steps. Ubiquitin-
activating enzyme (E1) activates ubiquitin by forming a high energy thiol esther bond between an E1 active site-located cystine residue and the C-terminal glycine
residue of ubiquitin. This reaction requires energy provided by the hydrolysis of ATP and forms an activated ubiquitin moiety that is transferred and bound by an
additional thiol ester bond to ubiquitin-conjugating enzyme (E2), which serves as a carrier protein. Ubiquitin–protein ligase (E3) catalyzes the covalent attachment of
ubiquitin to the target protein by the formation of isopeptide bonds. Multiple cycles of ubiquitination finally result in the synthesis and attachment of polyubiquitin
chains that serve as a recognition signal for the degradation of the target protein by the 26S proteasome. (B) The 26S proteasome consists of the barrel-shaped 20S
catalytic core complex and two 19S regulatory complexes capping the 20S complex at both ends. The 20S complex is composed of four axially stacked rings. Each
outer ring consists of non-proteolytic α subunits (orange). Each of the two inner rings are formed by seven proteolytic β subunits (blue) and three of them, β1, β2, and
β5 are constitutively expressed proteolytic subunits that can be replaced by the IFN-γ-inducible immunosubunits β1i, β2i, and β5i. The 19S complex consists of the
base and lid subcomplex. The base subcomplex contains six non-redundant ATPases of the AAA superfamily (green). The lid subcomplex (yellow) contains at least
eight subunits including de-ubiquitinating enzymes and receptors for ubiquitinated proteins. The polyubiquitinated target protein enters the 19S regulatory complex, is
recognized, deubiquitinated, unfolded, and translocated into the central cavity of the 20S catalytic core complex, where it is degraded by different hydrolytic activities.
Ubiquitin is recycled by ubiquitin carboxy terminal hydrolases, i.e. Rpn11 and UCH37 which are associated with the lid and the base, respectively. Peptides as a
product of degradation are released by diffusion.
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that proteasome inhibitors can be used as immunosuppressive
agents for the treatment of deregulated T cell-mediated
immune responses, including those that contribute to the
pathogenesis of polyarthritis, psoriasis, allograft rejection and
graft-versus-host disease [41,43,47,48]. Finally, recent studies
reveal that proteasome inhibitors can be used for the treatment
of arterial restenosis [49] and for the activation of a protectiveantioxidant defense response in cardiovascular endothelial
disorders [50].
Several recent studies have demonstrated complex mechan-
isms of adaptive modification of the proteasome system and the
extralysosomal protease tripeptidylpeptidase II (TPP II) in
response to severe cellular stress, such as short-term or continuous
inhibition of proteasomal proteolytic activities. Dependent on the
distinct proteasome inhibitors and cells types used, these studies
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an increase or a decrease of proteasome activity, the latter
accompanied by increased expression and activity of TPP II as a
compensatory mechanism. Herein we review mechanisms of
adaptive modification of the proteasome and the related protease
TPP II in response to inhibition of proteasome activity in
eukaryotic cells, pointing out some novel aspects of compensatory
flexibility of highly organized extralysosomal cytosolic protease
complexes such as the proteasome and TPP II.
2. The TPP II connection
Tripeptidyl peptidase II (TPP II; E.C. 3.4.14.10.) is a large
N1000 kDa cytosolic serine peptidase of the subtilisin type that
is built up of an oligomeric assembly of identical 138 kDa
subunits [51,52]; Table 1]. TPP II cleaves tripeptides from the
free NH2-terminus of oligopeptides generated by different
endopeptidases [51,53–56], and its proposed physiologic
function is to participate in cytosolic protein degradation in
concert with and downstream of different endopeptidases
[55,56] and the proteasome [57–60]. A cytoplasmic mem-
brane-bound isoform of TPP II has been identified to inactivate
the neuropeptide cholecystokinin in rat cerebral neurons [61],
revealing versatility of the enzyme. Besides its rather poorly
defined function in general cytosolic protein degradation, TPP
II has recently been identified as an endo- and exoproteolytic
peptidase that processes peptides of more than 15 amino acids
for MHC class I presentation that have been released from the
proteasome or are resistant to proteasomal processing [57–
60,62], albeit TPP II is unable to fully compensate for
proteasomal MHC class I peptide production when proteasome
activity is inhibited [63,64]. However, the precise tasks and
roles of TPP II in eukaryotic cells remain rather elusive until
now, but most interestingly, TPP II seems to have a further
close functional relationship to the proteasome. In this regard
there came first clues from an intriguing study conducted by
Ploegh and co-workers, who demonstrated the existence of a
proteolytic system that can compensate for loss of proteasome
function [65]. In this study, mouse EL-4 T cell lymphoma cells
were continuously grown in the presence of lethal concentra-
tions of the proteasome inhibitor NLVS that initially led to
apoptosis and growth inhibition of the cells. After 2–3 weeks
of culturing in the presence of NLVS, a population of EL-4
cells grew out and exhibited dramatically reduced proteolytic
activity of proteasomes and concomitant increased activity
towards the hydrolysis of AAF-AMC, a fluorogenic oligo-
peptidyl substrate hydrolysed by TPP II, but also by
proteasomes [54,65,66]. However, this increased AAF-AMC
hydrolysing activity was detected in cytosolic protein fractions
corresponding to higher molecular masses than those of 20S
proteasomes, indicating the activity of a giant protease such as
TPP II. This protease apparently compensated for loss of
proteasomal proteolytic activity in NLVS-adapted EL-4 cells
because proteasome-specific substrate proteins were still
processed in the absence of proteasomal activity, and AAF-
AMC hydrolysing activity, but not proteasomal proteolytic
activity was essential for survival and growth of the cells [65].In a subsequent study by Niedermann and co-workers, this
AAF-AMC hydrolysing protease was isolated from cytosolic
fractions of EL-4 cells adapted to the proteasome inhibitor
lactacystin. Analysis by nano-electrospray tandem mass
spectroscopy unambiguously revealed that it was in fact TPP
II [51]. Subsequently, TPP II has been demonstrated to
compensate in EL-4 cells for basic and specific proteasome
functions, such as degradation of polyubiquitinated proteins
and generation of MHC class I peptide ligands. This
compensatory function could be observed in EL-4 cells with
increased activity of TPP II due to adaptation to the
proteasome inhibitor NLVS, and in NLVS-treated EL-4 cells
with increased expression and activity of TPP II due to
transfectional overexpression of TPP II [67]. Conversely, EL-4
cells adapted to NLVS retain considerable sensitivity to
various highly specific proteasome inhibitors with regard to
MHC class I peptide generation, accumulation of polyubiqui-
tinated proteins, degradation of the proteasome-specific
substrate protein p53, and cell viability [68]. This clearly
demonstrates that residual proteolytic activity of proteasomes
remains essential for ubiquitin-dependent extralysosomal
cytosolic protein degradation in NLVS-adapted EL-4 cells
with increased activity of TPP II, which is apparently unable to
completely compensate for proteasome function in these cells.
As subsequently shown by Glas and co-workers, NLVS-
adapted EL-4 cells display acquired resistance to apoptosis
induced by diverse stimuli, and, compared to non-adapted EL-
4 cells, establish rapidly growing tumors when engrafted in
mice [69]. This acquired apoptosis resistance of NLVS-adapted
EL-4 cells is mainly a consequence of the lack of proteasomal
degradation of inhibitor of apoptosis proteins (IAPs), whose
integrity contributes to tumor cell apoptosis resistance by the
inhibition of caspases, the executioners of apoptosis [69–73].
Additionally, not only decreased proteasomal activity leading
to the failure of degradation of IAPs, but also concomitant
increased activity of TPP II confers apoptosis resistance and
enables hyperproliferation of EL-4 cells [67]. This altered
specificity of cytosolic proteolysis with an imbalance of
proteasome activity and TPP II activity apparently renders
cells apoptosis-resistant and leads to growth advantage of
tumor cells, pointing out a fatal consequence of continuous and
long-term proteasome inhibition.
3. The proteasome self-connection
From the results obtained in EL-4 cells it seemed clear that
TPP II partially compensates for proteasome function and
allows survival and apoptosis resistance in the scenario of
continuous proteasome inhibition, but there is another major
player on the stage: the proteasome itself. It was not entirely
unexpected that a sophisticated and highly organized protease
complex like the proteasome is able to undergo some adaptive
modification under the pressure of proteasome inhibition, but
it was intriguing to discover that there exists a proteasomal
positive autoregulatory feedback mechanism that allows the
compensation of insufficient proteasome activity following
proteasome inhibition. The first indirect evidence for such a
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multiple myeloma cells treated with the proteasome inhibitor
bortezomib. Gene expression profiles obtained by oligonu-
cleotide-microarray analysis revealed a 4- to 64-fold up-
regulation of transcription of proteasomal α and β subunits
and subunits of the 19S regulatory complex after 8 h
exposure of the cells to bortezomib [74]. These results
demonstrated that short-term proteasome inhibition induces
increased transcription of proteasome genes. In addition,
increased protein expression of proteasomal subunits was
demonstrated in Drosophila S2 cells with impaired proteaso-
mal chymotrypsin-like peptidase activity as a result of
targeted β5 subunit expression by RNA interference. Such
cells treated for 4 days with double-stranded RNA blocking
expression of proteasomal β5 subunit displayed increased
expression of non-targeted subunits of the 20S complex (α2
and α7) and the 19S regulatory complex (Rpt2, Rpt6 and
Rpn12), remained viable and retained partial viability in the
presence of otherwise lethal concentrations of the proteasome
inhibitors lactacystin, epoxomicin and bortezomib [75].
However, proteasomal β5 subunit-located chymotrypsin-like
peptidase activity has been attributed to constitute the main
proteolytic site of proteasomal protein degradation in
mammalian cells [76]. From the results obtained in Droso-
phila S2 cells it could be speculated that isolated and short-
term inhibition of this central proteasomal peptidase activity
leads to increased expression of non-targeted proteasomal
subunits, probably to substitute for the lack of chymotrypsin-
like peptidase activity and to ensure viability. Subsequently, a
study by Krüger and co-workers demonstrated transient and
concerted up-regulation of most 26S proteasome subunit
mRNAs, increased protein expression of proteasomal subunits
β1, α6 and Rpt1, and increased de novo biogenesis of
proteasomes accompanied by enhanced expression of the
proteasome maturation protein POMP in rat vascular smooth
muscle cells exposed for 6–8 h to the proteasome inhibitors
c-lactacystin and MG132, which target proteasomal chymo-
trypsin-like peptidase activity [77]. These results have been
complemented by a more recent study demonstrating
increased mRNA levels and protein expression of proteasomal
α and β subunits in murine neocortical neurons treated for
18 h with subtoxic concentrations of the proteasome inhibitor
MG-132 [78]. In addition, a very recent study by Wójcik and
co-workers demonstrated up-regulation of proteasomal 20S
complexes and α7 and Rpt5 subunits in C-26 murine colon
adenocarcinoma cells treated for 24 h and 48 h with subtoxic
concentrations of the proteasome inhibitor bortezomib [79].
Thus, for the first time it was clear that mammalian cells
respond to short-term and subtoxic inhibition of proteasomal
proteolytic activity with a coordinated up-regulation of protea-
some subunits at both the transcriptional and translational level,
and compensate proteasome inhibition by de novo formation of
proteasomes. But how domammalian cells respond to long-term
and toxic inhibition of proteasomal proteolytic activity? As
discussed above, results from studies in murine EL-4 T cell
lymphoma cells revealed compensatory increased proteolytic
activity and up-regulation of TPPII in such a condition, butstrikingly, recent studies in cells other than EL-4 cells have
demonstrated increased expression and activity of proteasomes
in response to long-term and toxic inhibition of proteasomal
proteolytic activity. In particular, human A431 squamous
carcinoma cells exposed for at least 2 months to lethal
concentrations of the proteasome inhibitor epoxomicin could
be adapted to grow in the presence of lethal and gradually
increasing concentrations of epoxomicin. These cells exhibited
increased protein expression of proteasomal β subunits
accompanied by markedly increased proteasomal chymotryp-
sin-like peptidase activity, apparently to compensate continuous
proteasome inhibition [80]. In contrast to their non-adapted
counterparts, epoxomicin-adapted A431 cells displayed resis-
tance to apoptosis induced by high concentrations of different
proteasome inhibitors and the cytostatic drug doxorubicin [80].
These findings suggest that increased proteasome activity and β
subunit expression in response to continuous proteasome
inhibition was the major mechanism for the establishment of
apoptosis resistance of the epoxomicin-adapted A431 cells.
Finally, a recent study in human Namalwa Burkitt lymphoma
cells adapted to grow in the presence of lethal concentrations of
bortezomib demonstrated the occurrence of increased biogenesis
and expression, altered subunit composition and increased
proteolytic activity of proteasomes, and interestingly, markedly
decreased expression and activity of TPP II [81]. After
continuous exposure to lethal concentrations of bortezomib for
at least 4 weeks, the cells grew out and exhibited increased de
novo biogenesis of proteasomes accompanied by increased
expression of the proteasome maturation protein POMP and
non-proteolytic α and β subunits. The cells abundantly
expressed 19S–20S–19S proteasomes, and completely abro-
gated expression ofβ1i,β2i, andβ5i immunosubunits and PA28
in favor of increased expression of constitutive proteolytic β1,
β2, and β5 subunits and 19S regulatory complexes. These
alterations of proteasomal expression and subunit composition
are accompanied by an increase in proteasomal caspase-like,
trypsin-like and chymotrypsin-like peptidase activities, not
inhibitable by high doses of proteasome inhibitors. Most
notably, this adaptive modification of the proteasome system
in Namalwa cells enables hyperproliferation and confers
resistance to apoptosis induced by diverse stimuli, most likely
due to de novo expression of anti-apoptotic protein Hsp27 and
the loss of ability to stabilize and accumulate pro-apoptotic
protein p53 [81]. Thus, increased biogenesis and expression,
altered subunit composition and increased proteolytic activity of
proteasomes constitute an adaptive mechanism of the protea-
some system in response to the lethal challenge of continuous
proteasome inhibition. This mechanism induced by continuous
proteasome inhibition apparently establishes hyperproliferation
and apoptosis resistance of tumor cells, as also observed in
NLVS-adapted EL-4 cells, which, however, showed up-regula-
tion of TPP II and down-regulation of the proteasome system.
4. Conclusions
It has become evident that the proteasome as a sophisticated
and highly organized protease complex can undergo subtle
Table 2
Characteristics of Proteasome Inhibitors
Proteasome inhibitor Origin/source Peptidase
activities targeted
Use/comments Reference
Lactacystin Streptomyces spec., irreversible
inhibitor
All peptidase
activities
Basic research, animal models [85–87]
Epoxomicin Peptide α′,β′-epoxyketone,
actinomycetes strain No. Q996-17
Chymotrypsin-
like
Basic research, anti-inflammatory activity, inhibition
of NFκB, antitumor activity (B16 murine melanom),
modulation of antigen presentation
[88–90]
Gliotoxin Epipolythiodioxo-piperazine, fungal
metabolite from Aspergillus fumigatus
Chymotrypsin-
like
Inhibition of NFêB in Hodgkin lymphoma Sternberg
Reed cells, antimalaria therapy study: apoptosis of
P. falciparum
[91,92]
TMC Natural product from
Apiospora montagnei, reversible inhibitor
All peptidase
activities
Basic research [93]
Epigallocatechin-
gallate (EGCG)
Green tea polyphenol, reversible inhibitor Chymotrypsin-
like
Anticancer properties, NFκB inhibition [94,95]
Bortezomib
(Velcade®, PS-341)
Dipeptidyl boronic acid, reversible
inhibitor, Millenium Pharmaceuticals
Chymotrypsin-
like
Clinical use, multiple myeloma, solid tumors,
non-Hodgkin lymphoma, murine xenograft
models
[96–98]
Salinosporamide
A (NPI-0052) and
B (NPI-0047)
Salinospora, strain CNB-392, irreversible
inhibitor, Nereus Pharmaceuticals
All peptidase
activities
Chronic lymphatic leukemia, multiple myeloma [99–101]
NLVS Peptide vinyl sulfone All peptidase
activities
Basic research [65,67–
69,102]
MG132 Z-Leu–Leu–Leu–aldehyde, peptide–
aldehyd, reversible inhibitor MyoGenetics
Chymotrypsin-
like
Basic research, modulation of antigen
presentation
[103–105]
MG262 Boronate analogue of MG132, Z-Leu–
Leu–Leu-B(OH)2, more potent, reversible inhibitor
Chymotrypsin-
like
Basic research [68]
MG115 N-CBZ–Leu–Leu–norvalinal, Z-LLnV, reversible
inhibitor
Chymotrypsin-
like
Basic research [104]
ALLN N-acetyl-leucyl-leucyl-norleucinal (ALLN),
reversible inhibitor
Chymotrypsin-
like
Basic research [106]
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modifications include down-regulation of proteasome activity
and compensatory up-regulation of TPP II activity as well as
increased de novo biogenesis and expression, altered subunit
composition and increased proteolytic activity of the protea-
some system. These modifications apparently constitute
adaptive feedback mechanisms to allow eukaryotic cells to
survive the lethal effects of proteasome inhibition and to
establish a hyperproliferative and apoptosis-resistant pheno-
type. Furthermore, it can be speculated that higher eukaryotic
cells harbor yet unknown sensory mechanisms that regulate
levels of proteasome and TPP II expression and modes of
proteasome subunit composition in response to proteasome
inhibition. In yeast, however, up-regulation of proteasome
subunits in response to proteasome inhibition can be explained
by the activity of the proteasome-specific transcription factor
Rpn4 whose ortholog has not been identified in the genome of
higher eukaryotes [82–84]. The fact that mammalian cells
respond in a similar manner to proteasome inhibition suggests
that a functional ortholog of Rpn4 must exist and awaits
discovery. Proteasome inhibitors have recently entered clinical
trials for the treatment of various cancers (Table 2). In view of
the adaptive and compensatory mechanisms developed by the
proteasome system in response to its inhibition, proteasome
inhibitors should be used carefully and, as far as possible, in
combination with functionally unrelated cytostatic drugs in
cancer therapy.References
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